Terms: = Uterine cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
42 results:
1. Integrating network pharmacology approaches for the investigation of multi-target pharmacological mechanism of 6-shogaol against cervical cancer.
Elasbali AM; Al-Soud WA; Mousa Elayyan AE; Al-Oanzi ZH; Alhassan HH; Mohamed BM; Alanazi HH; Ashraf MS; Moiz S; Patel M; Patel M; Adnan M
J Biomol Struct Dyn; 2023; 41(23):14135-14151. PubMed ID: 36943780
[TBL] [Abstract] [Full Text] [Related]
2. Lovastatin inhibits the proliferation of human cervical cancer hela cells through the regulation of tp53 pathway by mir-92a-1-5p.
Hu N; Lin J; Gao J; Lin S; Duan S
Pak J Pharm Sci; 2022 Nov; 35(6):1557-1564. PubMed ID: 36789815
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive immunohistochemical analysis based on the origin of leiomyosarcoma.
Bayçelebi D; Kefeli M; Yıldız L; Karagöz F
Pol J Pathol; 2022; 73(3):233-243. PubMed ID: 36734438
[TBL] [Abstract] [Full Text] [Related]
4. Novel Therapeutics in the treatment of uterine Sarcoma.
Bose S; Schwartz GK; Ingham M
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():900-909. PubMed ID: 35714303
[TBL] [Abstract] [Full Text] [Related]
5. The role of PICT1 in RPL11/mdm2/p53 pathway-regulated inhibition of cell growth induced by topoisomerase IIα inhibitor against cervical cancer cell line.
Rao Z; Shen J; Wang J; Zhang Z; Zhou J; Zhu J; Chen J; Chen W; Wang H
Biochem Pharmacol; 2022 Jul; 201():115098. PubMed ID: 35605655
[TBL] [Abstract] [Full Text] [Related]
6. Farnesoid X receptor functions in cervical cancer via the p14
Huang X; Wang B; Shen H; Huang D; Shi G
Mol Biol Rep; 2022 May; 49(5):3617-3625. PubMed ID: 35347542
[TBL] [Abstract] [Full Text] [Related]
7. Functional interaction between S100A1 and mdm2 may modulate p53 signaling in normal and malignant endometrial cells.
Nakagawa M; Higuchi S; Hashimura M; Oguri Y; Matsumoto T; Yokoi A; Ishibashi Y; Ito T; Saegusa M
BMC Cancer; 2022 Feb; 22(1):184. PubMed ID: 35177036
[TBL] [Abstract] [Full Text] [Related]
8. A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis.
Zhang J; Yu G; Yang Y; Wang Y; Guo M; Yin Q; Yan C; Tian J; Fu F; Wang H
Pharmacol Res; 2022 Mar; 177():106128. PubMed ID: 35150860
[TBL] [Abstract] [Full Text] [Related]
9. A Case of Giant Mesenchymal uterine Tumor: Lipoleiomyoma.
Bosoteanu M; Vodă RI; Orasanu CI; Aschie M; Enciu M; Baltatescu GI
Am J Case Rep; 2022 Jan; 23():e934913. PubMed ID: 35042839
[TBL] [Abstract] [Full Text] [Related]
10. PICT1 is critical for regulating the Rps27a-mdm2-p53 pathway by microtubule polymerization inhibitor against cervical cancer.
Wang H; Zhao J; Yang J; Wan S; Fu Y; Wang X; Zhou T; Zhang Z; Shen J
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119084. PubMed ID: 34166715
[TBL] [Abstract] [Full Text] [Related]
11. RPL34-AS1-induced RPL34 inhibits cervical cancer cell tumorigenesis via the mdm2-P53 pathway.
Zhu Y; Ren C; Jiang D; Yang L; Chen Y; Li F; Wang B; Zhang Y
Cancer Sci; 2021 May; 112(5):1811-1821. PubMed ID: 33675124
[TBL] [Abstract] [Full Text] [Related]
12. Long non-coding RNA TUG1 sponges microRNA-381-3p to facilitate cell viability and attenuate apoptosis in cervical cancer by elevating mdm2 expression.
Liu J; Wu D; Lin X; Hong Y; Wang X; Zheng C; Wu Z; Hong Y; Lv Y
Life Sci; 2021 Feb; 267():118902. PubMed ID: 33340525
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic potential of p53 reactivation in cervical cancer.
Zhao X; Sun W; Ren Y; Lu Z
Crit Rev Oncol Hematol; 2021 Jan; 157():103182. PubMed ID: 33276182
[TBL] [Abstract] [Full Text] [Related]
14. IU1 suppresses proliferation of cervical cancer cells through mdm2 degradation.
Xu L; Wang J; Yuan X; Yang S; Xu X; Li K; He Y; Wei L; Zhang J; Tian Y
Int J Biol Sci; 2020; 16(15):2951-2963. PubMed ID: 33061808
[TBL] [Abstract] [Full Text] [Related]
15. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated mdm2/p53 axis.
Liu K; Xue B; Bai G; Zhang W
Life Sci; 2020 Oct; 259():118277. PubMed ID: 32800832
[TBL] [Abstract] [Full Text] [Related]
16. A Slug-dependent mechanism is responsible for tumor suppression of p53-stabilizing compound CP-31398 in p53-mutated endometrial carcinoma.
Liu L; Yu ZY; Yu TT; Cui SH; Yang L; Chang H; Qu YH; Lv XF; Zhang XA; Ren CC
J Cell Physiol; 2020 Nov; 235(11):8768-8778. PubMed ID: 32633026
[TBL] [Abstract] [Full Text] [Related]
17. Association of PIK3CA and mdm2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Tantengco OAG; Nakura Y; Yoshimura M; Llamas-Clark EF; Yanagihara I
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2103-2107. PubMed ID: 31350972
[TBL] [Abstract] [Full Text] [Related]
18. Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/mdm2 pathway.
Qiang P; Shao Y; Sun YP; Zhang J; Chen LJ
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1778-1785. PubMed ID: 30840303
[TBL] [Abstract] [Full Text] [Related]
19. CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating mdm2 expression.
Liu L; Yang L; Chang H; Chen YN; Zhang F; Feng S; Peng J; Ren CC; Zhang XA
Int J Oncol; 2019 Mar; 54(3):942-954. PubMed ID: 30628640
[TBL] [Abstract] [Full Text] [Related]
20. P53 and Murine Double Mimute 2 (mdm2) Expression Changes and Significance in Different Types of Endometrial Lesions.
Jiang Z; Xu W; Dan G; Liu Y; Xiong J
Med Sci Monit; 2016 Dec; 22():4786-4793. PubMed ID: 27924072
[TBL] [Abstract] [Full Text] [Related]
[Next]
